Tissue plasminogen activator and risk of myocardial infarction: The Rotterdam study

Circulation

Volumn 95, Issue 12, 1997, Pages 2623-2627

  Van der Bom, Johanna G ^a,b   De Knijff, Peter ^b   Haverkate, Frits ^b   Bots, Michiel L ^a   Meijer, Piet ^b   De Jong, Paulus T V M ^a   Hofman, Albert ^a   Kluft, Cornelis ^b   Grobbee, Diederick E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Cardiovascular diseases; Fibrinolysis; Plasminogen activators; Risk factors; Thrombolysis

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; FEMALE; FIBRINOLYSIS; GENE DELETION; GENE INSERTION; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0030906669     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.12.2623     Document Type: Article

References (31)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, I. N Engl J Med. 1992;23:242-250.
2. Marder VJ, Sherry S. Thrombolytic therapy: current status. N Engl J Med. 1988;318:1512-1520.
3. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J. 1990;6:525-528.
4. Gram J, Jespersen J. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulin characterizes a risk group among young survivors of acute myocardial infarction. Thromb Haemost. 1987;57:137-139.
5. Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Scand. 1987;221:149-153.
6. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
7. Jansson H, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991;12:157-161.
8. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation. 1993;88:2030-2034.
9. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
10. Ridker PM, Douglas EV. Hemostatic factors and the risk of myocardial infarction. N Engl J Med. 1995;333:389-390.
11. Degen SJF, Rajput B, Reich E. The human tissue-type plasminogen activator gene. J Biol Chem. 1986;261:6972-6985.
12. Yang-Feng TL, Opdenakker G, Volckaert G, Franeke U. Human tissue-type plasminogen activator gene located near chromosomal breakpoint in myeloproliferative disorder. Am J Hum Genet. 1986;39:79-87.
13. Ludwig M, Wohn KD, Schleuning WD, Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (t-PA) gene as a result of an Alu insertion/deletion event. Hum Genet. 1992;88:388-392.
14. Hofman A, Grobbee DE, de Jong PTVM, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403-422.
15. van Bemmel JH, Kors JA, van Herpen G. Methodology of the Modular ECG Analysis System MEANS. Methods Inf Med. 1990;29:346-353.
16. Willems JL, Abreu-Lima C, Arnaud P, van Bemmel JH, Brohet C, Degani R, Denis B, Gehring J, Graham I, van Herpen G, Machado H, Maefarlane PW, Michaelis J. Moulopoulos SD, Rubel P, Zywietz C. The diagnostic performance of computer programs for the interpretation of electrocardiograms. N Engl J Med. 1991;325:1767-1773.
17. Rose GA, Blackburn H, Gillum RF. Cardiovascular Survey Methods. Geneva, Switzerland: World Heath Organization; 1982.
18. Bots ML, van Swieten JC, Breteler MM, de Jong PTVM, van Gijn J, Hofman A, Grobbee DE. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet. 1993;341:1232-1237.
19. van der Bom JG, Bots ML, de Bruijn AM, Hofman A, Grobbee DE. Measurement of β-thromboglobulin in the elderly: findings from the Rotterdam Study. Fibrinolysis. 1994;8(suppl 2):157-159.
20. Ranby M, Sundell IB, Nilsson TK. Blood collected in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost. 1989;62:917-922.
21. Ranby M, Bergsdorf N, Nilsson TK, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme linked immunosorbent assay. Clin Chem. 1986;32:2160-2165.
22. Benham FJ, Spurr N, Povey S, Brinton BT, Goodfellow PN, Solomon E, Harris TJR. Assignment of tissue type plasminogen activator to chromosome 8 in man and identification of a common restriction length polymorphism within the gene. Mol Biol Med. 1984;2:251-259.
23. Angleton P, Chandler WL, Schmer G, Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor. Circulation. 1989;79:101-106.
24. Makalowski W, Mitchell GA, Labuda D. Alu sequences in the coding regions of mRNA: a source of protein variability. Trends Genet. 1994;10:188-193.
25. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, Evans A, Arveiler D, Cambou JP, Luc G, Rakotovao R, Ducimetiere P, Soubrier F, Alhenc-Gelas F. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation. 1994;90:669-676.
26. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
27. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin converting enzyme gene controls plasma ACE levels, Am J Hum Genet. 1992;51:197-205.
28. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphism of the angiotensin I-converting enzyme gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis, Am J Genet. 1996;58:1268-1278.
29. van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, de Knijff P. Alu-repeat polymorphism in the tissue type plasminogen activator gene does not affect basal endothelial t-PA synthesis. Thromb Haemost. 1995;74:1202. Letter.
30. Ranby M, N'Guyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Thromb Haemost. 1989;61:409-414.
31. Kluft C. Constitutive synthesis of tissue type plasminogen activator and plasminogen activator inhibitor type I : conditions and therapeutic targets. Fibrinolysis. 1994;8(suppl 2):1-7.